Phase III Clinical Pharmacology Study of Tolvaptan
Authors:
- for the Tolvaptan InvestigatorsFIfor the Tolvaptan Investigators
- Takayuki InomataTITakayuki Inomata
- 26 November 2011
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 25 (S1) , 57-65
Abstract
This study aimed to investigate the pharmacokinetics, pharmacodynamics, efficacy and safety of tolvaptan, an orally effective vasopressin V2-receptor antagonist. This was a multicenter, randomized, double-blind, parallel group study. Tolvaptan was administered at 7.5 or 15 mg, in combination with furosemide, for 7 days in Japanese heart failure (HF) patients with volume overload that had not resolved despite receiving furosemide. The blood concentration of tolvaptan was maintained at a higher concentration for a longer time in patients who received 15 mg/day when compared with patients who received 7.5 mg/day. Tolvaptan increased urine volume and increased weight loss dose-dependently when used in combination with furosemide. Importantly, tolvaptan enhanced water diuresis without affecting blood electrolyte levels. Tolvaptan exerts diuretic effects and causes body weight loss at the low dose of 7.5 mg; however, these effects were less than those elicited by 15 mg tolvaptan.Keywords
This publication has 17 references indexed in Scilit:
- Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group StudyCardiovascular Drugs and Therapy, 2011
- Pharmacokinetics, Pharmacodynamics and Safety of Tolvaptan, A Novel, Oral, Selective Nonpeptide AVP V2-receptor Antagonist: Results of Single- and Multiple-Dose Studies in Healthy Japanese Male VolunteersCardiovascular Drugs and Therapy, 2011
- Loop Diuretics in Acute Decompensated Heart FailureCirculation: Heart Failure, 2009
- Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for HyponatremiaNew England Journal of Medicine, 2006
- Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failureAmerican Journal of Physiology-Renal Physiology, 2006
- Diuretic usage in heart failure: a continuing conundrum in 2005European Heart Journal, 2005
- Vasopressin V 2 -Receptor Blockade With Tolvaptan in Patients With Chronic Heart FailureCirculation, 2003
- Diuretics in chronic heart failure — benefits andhazardsEuropean Heart Journal, 2001
- Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.Heart, 1987
- Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention TrialThe American Journal of Cardiology, 1985